Our analyses further revealed that the expression of SPA17 was associated with lymph node metastasis (p < 0.001), ER status (p < 0.001), PR status (p = 0.003), molecular subtyping (p < 0.001), Endocrine-therapy (p < 0.001) and Radiotherapy (p < 0.001) (Table 1). This evidence concerns the gene SPA17 and metastatic malignant neoplasm in the lymph nodes.